Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02085239
Other study ID # 13027-13-033
Secondary ID
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date August 2013
Est. completion date March 2015

Study information

Verified date April 2017
Source TriHealth Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the potential role of a long acting anesthetic (ropivacaine) in providing an extended period of pain relief for patients undergoing ultrasound guided core biopsy of the breast.


Description:

The purpose of this study is to evaluate the potential role of a long acting anesthetic (ropivacaine) in providing an extended period of pain relief for patients undergoing ultrasound guided core biopsy of the breast. One group of patients will receive lidocaine alone for local anesthesia. A second group of patients will similarly receive lidocaine prior to tissue sampling, followed by infiltration of the biopsy area with ropivacaine.

Our hypothesis is that patients who receive a long acting anesthetic (ropivacaine) along with the popular short acting anesthetic (lidocaine), will be pain free after the breast biopsy procedure for a longer period of time than the patients who only receive lidocaine (the short acting anesthetic). This will lessen the emotional and physical trauma associated with the procedure and give patients a better experience thereby improving patient care.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2015
Est. primary completion date March 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

- Patients with breast lesions recommended for biopsy by physician

Exclusion Criteria:

- Patients with breast lesions not recommended for biopsy

- Patients with allergic reactions to lidocaine, ropivacaine, or related anesthetics

Study Design


Related Conditions & MeSH terms

  • Pain Management After Breast Biopsy

Intervention

Drug:
Lidocaine Ropivacaine
8-10 ml of Lidocaine given by subcutaneous injection 8-10 ml of Ropivacaine given by subcutaneous injection
Lidocaine alone


Locations

Country Name City State
United States Mary Jo Cropper Family Center for Breast Care; Bethesda North Hospital Cincinnati Ohio

Sponsors (1)

Lead Sponsor Collaborator
TriHealth Inc.

Country where clinical trial is conducted

United States, 

References & Publications (3)

Applied Radiology. Breast biopsy: Anesthesia, bleeding prevention, representative sampling and rad-path concordance. Vol 41.1. Jan 2012

Novy DM, Price M, Huynh PT, Schuetz A. Percutaneous core biopsy of the breast: correlates of anxiety. Acad Radiol. 2001 Jun;8(6):467-72. — View Citation

Reynolds HE, Jackson VP, Musick BS. Preoperative needle localization in the breast: utility of local anesthesia. Radiology. 1993 May;187(2):503-5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in pain level from baseline to 1 hour Amount of pain that patient is feeling at baseline and 1 hour after the procedure 1 hour after procedure
Secondary Change in pain level from 1 hour to 5 hours after procedure Amount of pain that patient is feeling 5 hours after the procedure 5 hours
Secondary Change in pain level from 5 to 10 hours after the procedure Amount of pain that patient is feeling 10 hours after the procedure 10 hours after procedure
Secondary Change in pain level from 10 to 24 hours after procedure Amount of pain that patient is feeling 24 hours after the procedure 24 hours after procedure
Secondary Pathology Description of tissue collected Benign or malignant tumor (if found) Type of tumor up to 72 hours after procedure